| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development expenses | 2,405 | |||
| General and administrative expenses | 8,672 | |||
| Loss from operating activities | -11,077 | |||
| Foreign exchange loss | -1 | |||
| Change in fair value of derivative warrant liabilities | -900 | |||
| Interest and other income, net | 685 | |||
| Total other income, net | 1,584 | |||
| Loss before income tax benefit | -9,493 | |||
| Income tax benefit | -1,700 | |||
| Net loss | -7,793 | |||
| Basic EPS | -0.47 | |||
| Diluted EPS | -0.47 | |||
| Basic Average Shares | 16,510,632 | |||
| Diluted Average Shares | 16,510,632 | |||
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)